Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  5. IQX Limited
  6. News
  7. Summary
    IQX   AU000000IQX4


End-of-day quote. End-of-day quote NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED - 08/10
0.13 AUD   +85.71%
10/18IQX : Filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA).
09/09IQX : Annual Report June 2021
09/09IQX Limited Reports Earnings Results for the Full Year Ended June 30, 2021
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

iQX : Annual Report June 2021

09/09/2021 | 03:12am EDT

iQX Limited

ACN 155 518 380

Annual Report for the year ended - 30 June 2021

iQX Limited


30 June 2021

Corporate directory


Chair and Group CEO's report


Directors' report


Auditor's independence declaration


Consolidated statement of profit or loss and other comprehensive income


Consolidated statement of financial position


Consolidated statement of changes in equity


Consolidated statement of cash flows


Notes to the consolidated financial statements


Directors' declaration


Independent auditor's report to the members of iQX Limited


Shareholder information



iQX Limited Corporate directory 30 June 2021


Dr George Syrmalis, Chair and Group Chief Executive Officer

Peter Simpson

John Stratilas

Company secretary

Ron Hollands

Registered office and principal

Level 9, 85 Castlereagh Street

place of business

Sydney NSW 2000

Share register

Boardroom Pty Limited

Level 12, 225 George Street

Sydney NSW 2000


UHY Haines Norton

Level 11, 1 York Street

Sydney NSW 2000

Stock exchange listing

iQX Limited shares are listed on the National Stock Exchange (NSX: IQX)



Corporate Governance Statement

The Directors and management are committed to conducting the business of iQX

Limited in an ethical manner and in accordance with the highest standards of

corporate governance. iQX Limited's corporate governance policies and procedures

comply with Practice Note 14 issued by the National Securities Exchange of Australia

(NSX). The Board of Directors has included in its corporate governance policies those

matters contained in the ASX Corporate Governance Council's Corporate

Governance Principles and Recommendations (4th edition) (ASXCGC

Recommendations), where applicable. However, the Board of Directors also

recognises that full adoption of the ASXCGC Recommendations may not be practical

or provide the optimal result given the circumstances of iQX Limited.

The Corporate Governance Statement, which sets out the corporate governance

practices that were in operation during the financial year, has been approved at the

same time as the Annual Report and can be found at:



iQX Limited

Chair and Group CEO's report 30 June 2021

On behalf of the Board of Directors, I am pleased to share that iQX Ltd continues to deliver growth in its portfolio of investments in the bioscience sector for the financial year ended 30 June 2021, amidst the challenging market conditions presented by the COVID-19 pandemic.

iQX Ltd is an investment funds management company specialising in the bioscience sector and is a core member of The iQ Group Global, a consortium of companies that find, fund and develop bioscience discoveries into life-changing medical innovations.

The IQX holdings are as follows:

GBS Inc. (7.7%)*

BiosensX (Europe) Inc. (19%)*

BiosensX (North America) Inc. (13.4%)*

Glucose Biosensor Systems (MENA) Holdings Inc. (19%)*

OncoTEX Inc. (19%)*

*Effective equity position at the end of FY21

The market capitalisation of the IQX Ltd as of the date of this report was $56.2m

  • GBS Inc. was listed on NASDAQ in December 2020 and is the APAC licensee of the Biosensor technology. The Saliva Glucose Biosensor commercialisation program has continued to progress with the FDA regulatory approval process. The process has sustained certain delays due to COVID, however, clinical testing is expected to commence very soon. The Saliva Glucose Biosensor has been indicated by the FDA to follow the De Novo regulatory pathway as it is innovative and without predicate.
  • GBS Inc. has been granted, by the Wyss Institute for Biologically Inspired Engineering at Harvard University, a license to integrate the Institute's antifouling technology into The Group's Biosensor, and develop a quantitative salivary COVID test. The company is formally collaborating with the Wyss Institute, Harvard University and Johns Hopkins University in developing the prementioned salivary quantitative IgG rapid diagnostic test. The commercial benefits stemming from this collaboration will flow to the LSBD commercial entities, GBS Inc., and subsequently to the ultimate parent which is IQG and IQX.

BiosensX (Europe) Inc.

BiosensX (North America) Inc.

Glucose Biosensor Systems (MENA) Holdings Inc.

These companies are the Biosensor licensees for the respective geographic regions to the intellectual property developed by GBS under its license. At this stage and as GBS progresses to clinical trials, the abovementioned companies are actively preparing to commence licensing arrangements for the Biosensor products to be launched over the next 24-48 months. The diagnostic test portfolio is expected to consist of approximately 130 different diagnostic tests, including the Saliva Glucose Biosensor and other diagnostic tests developed from the Biosensor technology.

Significant progress has been made with OncoTEX, the Group's oncology portfolio company, both in research and development as well as on the corporate front.

TEX Core is an anticancer drug platform that has the ability to develop a range of well-tolerated, MRI- detectable cancer therapeutics that target drug-sensitive and drug-resistant solid tumours. The first cancer therapeutic to be commercialised from the platform is OxaliTEX, a new chemical entity (WO 2015/191797) that targets only solid tumour cells, activates within the tumour and overcomes drug-resistance mechanisms with minimal side effects. OxaliTEX is currently at late preclinical stage and we will soon contemplate commencing clinical trials. Sterling Pharmaceutical have been contracted to manufacture OxaliTEX for the clinical trials.


iQX Limited

Chair and Group CEO's report 30 June 2021

The first indication to trial is ovarian cancer, which is also classified by the FDA as an orphan disease, which may result in expedited regulatory approval by the FDA.

OncoTEX has further enriched its pipeline within the Tex Core platform, with six further compounds.

  • ParpTEX utilises TEX Core's tumour-localisation to enable the effective delivery of Parp inhibitors. ParpTEX is being developed for prostate and other BRCA mutant cancers.
  • GemTEX utilises TEX Core's tumour-localisation in combination with Gemcitabine's antimetabolite properties, initially to treat pancreatic and bladder cancers.
  • DoxTEX utilises TEX Core's tumour-localisation in combination with Anthracyclines to treat early-stage breast cancer and small-cell lung carcinoma.
  • TaxTEX utilises TEX Core's tumour-localisation in combination with Taxanes to treat Taxol resistant breast cancer, bladder cancer and prostate cancer.
  • ImmunoTEX utilises TEX Core's tumour-localisation in combination with Immunotherapies to treat breast cancer, pancreatic cancer, and lung cancer.
  • MangaTEX, through tumour specific localisation, allows for site-selective thermal heating of cancer cells upon irradiation by non-tissue damaging light. The initial indication MangaTEX is focused upon is breast cancer including BRCA mutant and Triple Negative.

On the corporate front, despite the pandemic restrictions, the Company has continued its capitalisation program here in Australia as well as the USA and has created a stellar board of directors and scientific advisors.

The company is already looking for appropriate out-licensing partners for its most advanced asset, OxaliTEX.

Given SEC (Security Exchange Commission) restrictions, I cannot further elaborate at this time as the company is undergoing a quiet period, on the capital market front. However, soon I hope to share some news with all our IQX investors.

OncoTEX continues to work with the University of Texas at Austin and MD Anderson Cancer Center research and development group to advance and deliver to patients both of the above technologies and the resultant drugs. The TEX Core platform represents extremely valuable intellectual property for the Group, as the IP portfolio consists of approximately twenty (20) patents and is expected to grow further.

I would like to thank all the investors, the board, and our staff for their dedication during the past year.

Dr George Syrmalis

Chair and Group CEO


This is an excerpt of the original content. To continue reading it, access the original document here.


IQX Ltd. published this content on 09 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2021 07:11:02 UTC.

© Publicnow 2021
All news about IQX LIMITED
10/18IQX : Filed a Pre-Submission package with the United States (US) Food and Drug Administrat..
09/09IQX : Annual Report June 2021
09/09IQX Limited Reports Earnings Results for the Full Year Ended June 30, 2021
07/08IQX LIMITED (NSX : IQX) Portfolio Company Awarded $6.3M Federal Govt Grant
04/29IQX LIMITED (NSX : IQX) Progress of Clinical Programs
03/09Iqx Limited Reports Earnings Results for the Half Year Ended December 31, 2020
2020Iqx Limited Reports Earnings Results for the Full Year Ended June 30, 2020
2020Iqx Limited Reports Earnings Results for the Half Year Ended December 31, 2019
2019Iqx Limited Reports Earnings Results for the Full Year Ended June 30, 2019
2019IQX Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, ..
More news
Sales 2021 3,83 M 2,88 M 2,88 M
Net income 2021 -23,1 M -17,4 M -17,4 M
Net Debt 2021 5,98 M 4,50 M 4,50 M
P/E ratio 2021 -1,31x
Yield 2021 -
Capitalization 56,2 M 42,2 M 42,3 M
EV / Sales 2020 13,5x
EV / Sales 2021 9,45x
Nbr of Employees -
Free-Float -
Duration : Period :
iQX Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
George Syrmalis Chief Executive Officer & Executive Director
Kosmas Dimitriou Chairman
John Stratilas Independent Non-Executive Director
Peter Buchanan Simpson Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.218.76%134 660
LONZA GROUP AG27.07%58 240
SEAGEN INC.-0.17%31 691
CELLTRION, INC.-39.00%25 332